Sakar Healthcare Ltd

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 03 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 22 April 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Sakar Healthcare Ltd is rated Buy by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 11 April 2026, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and technical outlook.

A 145.78% stock return in one year. A 69.3% growth in net profit over the same period. The gap between those two numbers — roughly 76 percentage points — is driven largely by the market's willingness to pay a significantly higher multiple for each rupee of Sakar Healthcare Ltd's earnings. That willingness is the story behind this micro-cap's multibagger status.

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 31 March 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 March 2026, providing investors with an up-to-date view of its performance and prospects.

Sakar Healthcare Ltd is rated Buy by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 09 March 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with the latest insights into its performance and outlook.

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 February 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Sakar Healthcare Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 February 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Sakar Healthcare Ltd has emerged as a standout performer in the Pharmaceuticals & Biotechnology sector, delivering multibagger returns of over 100% in the past year. Outperforming the Sensex by a wide margin, the stock’s remarkable growth is underpinned by robust financials, strong institutional interest, and consistent operational improvements, making it a compelling buy for investors seeking sustained momentum in a competitive industry.

Sakar Healthcare Ltd has demonstrated a significant shift in price momentum, moving from a mildly bullish to a bullish technical trend, supported by a confluence of positive signals across key indicators such as MACD, RSI, moving averages, and Bollinger Bands. This technical upgrade accompanies a notable 6.09% gain in the stock price on 6 Feb 2026, reflecting renewed investor confidence in the Pharmaceuticals & Biotechnology sector.

Sakar Healthcare Ltd has delivered an exceptional quarterly performance for the December 2025 quarter, prompting an upgrade in its financial trend rating from positive to outstanding. The pharmaceutical and biotechnology company has demonstrated robust revenue growth, margin expansion, and improved capital efficiency, signalling a strong turnaround and enhanced investor confidence.

Sakar Healthcare Ltd., a Gujarat-based pharmaceutical manufacturer, delivered an exceptional third quarter performance for FY2026, with net profit more than doubling to ₹10.25 crores—a remarkable 125.77% quarter-on-quarter surge and 126.27% year-on-year growth. The micro-cap company, currently valued at ₹982.11 crores, saw its shares rally 7.71% following the results announcement, closing at ₹441.40 on February 5, 2026.

Sakar Healthcare Ltd has exhibited a notable shift in its technical momentum, moving from a previously bearish stance to a mildly bullish outlook as of early February 2026. This transition is underscored by mixed signals from key technical indicators such as MACD, RSI, moving averages, and Bollinger Bands, reflecting a nuanced market sentiment amid the Pharmaceuticals & Biotechnology sector.

Sakar Healthcare Ltd has demonstrated a notable shift in price momentum and technical indicators, signalling a transition from a mildly bullish to a bullish trend. With a significant day gain of 5.39% and a recent upgrade in its Mojo Grade from Sell to Hold, the pharmaceutical and biotechnology company is attracting renewed investor interest amid improving technical signals and robust long-term returns.

Sakar Healthcare Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 Sep 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 03 February 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.